BSX logo

BSX
Boston Scientific Corp.

6,648
Mkt Cap
$153.8B
Volume
17.38M
52W High
$109.50
52W Low
$85.98
PE Ratio
47.10
BSX Fundamentals
Price
$88.48
Prev Close
$90.03
Open
$90.02
50D MA
$97.03
Beta
0.63
Avg. Volume
9.29M
EPS (Annual)
$1.25
P/B
5.58
Rev/Employee
$315,981.13
Loading...
Loading...
News
all
press releases
QRG Capital Management Inc. Reduces Position in Boston Scientific Corporation $BSX
QRG Capital Management Inc. cut its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 10.2% in the third quarter, according to the company in its most recent disclosure with the...
MarketBeat·13h ago
News Placeholder
More News
News Placeholder
ASR Vermogensbeheer N.V. Buys 18,640 Shares of Boston Scientific Corporation $BSX
ASR Vermogensbeheer N.V. boosted its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 4.1% during the 3rd quarter, according to the company in its most recent disclosure with the...
MarketBeat·18h ago
News Placeholder
Boston Scientific (NYSE:BSX) Upgraded by Wall Street Zen to Buy Rating
Wall Street Zen upgraded shares of Boston Scientific from a "hold" rating to a "buy" rating in a report on Saturday...
MarketBeat·20h ago
News Placeholder
Penumbra Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Penumbra, Inc. - PEN
Penumbra Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Penumbra, Inc. - PEN Penumbra Investor Alert: Kahn Swick & Foti, LLC Investigates...
PR Newswire·1d ago
News Placeholder
Intuitive Surgical Stock Dips on Q4 Preliminary Revenue Results
ISRG posts strong preliminary Q4 and full-year 2025 revenue growth, but shares dip as investors weigh procedure trends, margins and outlook.
Zacks·1d ago
News Placeholder
DexCom Stock Declines Following Strong Preliminary Q4 Results
DXCM posts strong preliminary Q4 and full-year 2025 revenue growth, beating estimates, though shares slip after the announcement.
Zacks·1d ago
News Placeholder
Down 6.3% in 4 Weeks, Here's Why Boston Scientific (BSX) Looks Ripe for a Turnaround
Boston Scientific (BSX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks·1d ago
News Placeholder
Boston Scientific (NYSE:BSX) Price Target Lowered to $100.00 at Oppenheimer
Oppenheimer cut their price target on Boston Scientific from $125.00 to $100.00 and set an "outperform" rating on the stock in a report on Friday...
MarketBeat·2d ago
News Placeholder
Hologic Leads Campaign to Emphasize Routine Cervical Cancer Screening
HOLX launches Ultimate Defense, a new U.S. campaign that urges routine Pap + HPV screening to boost awareness and help curb rising underscreening.
Zacks·2d ago
News Placeholder
Nordea Investment Management AB Buys 14,262 Shares of Boston Scientific Corporation $BSX
Nordea Investment Management AB raised its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 11.1% during the third quarter, according to its most recent filing with the Securities...
MarketBeat·2d ago
<
1
2
...
>

Latest BSX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.